AET01 Table 2 (Supplementary) Overview of Deaths and Adverse Events Summary Table 2. Overview of death and summary
of adverse events with medical concepts.
aet01_2.RdAET01 Table 2 (Supplementary) Overview of Deaths and Adverse Events Summary Table 2. Overview of death and summary
of adverse events with medical concepts.
Usage
aet01_2_main(
adam_db,
arm_var = "ACTARM",
lbl_overall = NULL,
deco = std_deco("AET01"),
safety_var = c("FATAL", "SER", "SERWD", "SERDSM", "RELSER", "WD", "DSM", "REL",
"RELWD", "RELDSM", "SEV"),
lbl_safety_var = NULL,
medconcept_var = c("SMQ01", "SMQ02", "CQ01"),
lbl_medconcept_var = NULL,
...
)
aet01_2_lyt(
arm_var,
lbl_overall,
deco,
safety_var,
lbl_safety_var,
medconcept_var,
lbl_medconcept_var
)
aet01_2_pre(adam_db, ...)
aet01_2_check(
adam_db,
req_tables = c("adsl", "adae"),
arm_var = "ACTARM",
safety_var = c("FATAL", "SER", "SERWD", "SERDSM", "RELSER", "WD", "DSM", "REL",
"RELWD", "RELDSM", "SEV"),
medconcept_var = c("SMQ01", "SMQ02", "CQ01")
)
aet01_2Arguments
- adam_db
(
dm) object containing theADaMdatasets- arm_var
(
character) variable used for column splitting- lbl_overall
(
character) label used for overall column, if set toNULLthe overall column is omitted- deco
(
character) decoration withtitle,subtitlesandmain_footercontent- safety_var
(
character) the safety variables to be summarized.- lbl_safety_var
(
character) the labels of the safety variables to be summarized.- medconcept_var
(
character) the medical concept variables to be summarized.- lbl_medconcept_var
(
character) the label of the medical concept variables to be summarized.- ...
not used.
- req_tables
(
character) names of the required tables.
Functions
aet01_2_main(): Main TLG functionaet01_2_lyt(): Layoutaet01_2_pre(): Preprocessingaet01_2_check(): Checks
Note
adam_dbobject must contain anadsltable with the"DTHFL"and"DCSREAS"columns.adam_dbobject must contain anadaetable with the columns passed tosafety_var.
Examples
run(aet01_2, syn_data)
#> A: Drug X B: Placebo C: Combination
#> (N=134) (N=134) (N=132)
#> ———————————————————————————————————————————————————————————————————————————————————————————————————————
#> Total number of patients with at least one AE 122 (91.0%) 123 (91.8%) 120 (90.9%)
#> Total number of AEs 609 622 703
#> Total number of deaths 25 (18.7%) 23 (17.2%) 22 (16.7%)
#> Total number of patients withdrawn from study due to an AE 3 (2.2%) 6 (4.5%) 5 (3.8%)
#> Total number of patients with at least one
#> AE with fatal outcome 76 (56.7%) 70 (52.2%) 75 (56.8%)
#> Serious AE 104 (77.6%) 101 (75.4%) 99 (75.0%)
#> Serious AE leading to withdrawal from treatment 9 (6.7%) 6 (4.5%) 11 (8.3%)
#> Serious AE leading to dose modification/interruption 22 (16.4%) 26 (19.4%) 29 (22.0%)
#> Related Serious AE 76 (56.7%) 70 (52.2%) 75 (56.8%)
#> AE leading to withdrawal from treatment 27 (20.1%) 26 (19.4%) 30 (22.7%)
#> AE leading to dose modification/interruption 66 (49.3%) 76 (56.7%) 74 (56.1%)
#> Related AE 105 (78.4%) 108 (80.6%) 109 (82.6%)
#> Related AE leading to withdrawal from treatment 6 (4.5%) 12 (9.0%) 8 (6.1%)
#> Related AE leading to dose modification/interruption 29 (21.6%) 38 (28.4%) 38 (28.8%)
#> Severe AE (at greatest intensity) 91 (67.9%) 90 (67.2%) 93 (70.5%)
#> Total number of patients with at least one
#> SMQ 01 Reference Name 72 (53.7%) 79 (59.0%) 75 (56.8%)
#> SMQ 02 Scope 0 0 0
#> CQ 01 Reference Name 74 (55.2%) 80 (59.7%) 87 (65.9%)